Literature DB >> 9150386

Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts.

P Ciana1, A Neri, C Cappellini, F Cavallo, M Pomati, C C Chang, A T Maiolo, L Lombardi.   

Abstract

The NFKB-2 (Lyt-10) gene codes for an NF-kappaB-related transcription factor containing rel-polyG-ankyrin domains. Rearrangements of the NFKB-2 locus leading to the production of 3' truncated NFKB-2 proteins are recurrently found in lymphoid neoplasms, particularly cutaneous lymphomas. Such mutant NFKB-2 proteins have lost the ability to repress transcription that is typical of NFKB-2 subunit p52, and function as constitutive transcriptional activators. To verify whether the expression of abnormal NFKB-2 proteins can lead to malignant transformations in mammalian cells, we transfected human lymphoblastoid cell lines and murine fibroblasts (Balb/3T3) with expression vectors carrying the cDNAs coding for normal NFKB-2p52, Lyt-10C alpha or LB40 proteins, which are representative of the abnormal types found in lymphoma cases. The expression of both normal and mutant NFKB-2 proteins has a lethal effect on lymphoblastoid cells and a cytotoxic effect was also observed in murine fibroblasts. The fibroblast cell lines expressing Lyt-10C alpha or LB40, but not those expressing normal NFKB-2p52, were capable of forming colonies in soft agar. The analysis of individual clones revealed that cloning efficiency correlated with the expression levels of the abnormal proteins. Injection of the Lyt-10C alpha-transfected Balb cells in SCID mice led to tumor formation in all of the animals, whereas no tumors were observed in the mice injected with control or NFKB-2p52-transfected cells, thus indicating that abnormal NFKB-2 protein expression is tumorigenic in vivo. Our results show that mutant NFKB-2 proteins can lead to the transformed phenotype, and support the hypothesis that alterations in NFKB-2 genes may play a role in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150386     DOI: 10.1038/sj.onc.1201015

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

Review 1.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.

Authors:  Katie Schumm; Sonia Rocha; Jorge Caamano; Neil D Perkins
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

3.  Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters.

Authors:  Guoliang Qing; Zhaoxia Qu; Gutian Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-15       Impact factor: 11.205

4.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

5.  NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis.

Authors:  Baochun Zhang; Zhe Wang; Tai Li; Erdyni N Tsitsikov; Han-Fei Ding
Journal:  Blood       Date:  2007-04-03       Impact factor: 22.113

6.  Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Soo Ok Lee; Xin Lin; Donald L Trump; Allen C Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  A cell cycle regulatory network controlling NF-kappaB subunit activity and function.

Authors:  Benjamin Barré; Neil D Perkins
Journal:  EMBO J       Date:  2007-10-25       Impact factor: 11.598

8.  NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

Authors:  G M De Donatis; E Le Pape; A Pierron; Y Cheli; V Hofman; P Hofman; M Allegra; K Zahaf; P Bahadoran; S Rocchi; C Bertolotto; R Ballotti; T Passeron
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

9.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

Review 10.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.